Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study
Journal of Gastroenterology · 2026
DOI: 10.1007/s00535-025-02310-3 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Gastroenterology, 2026. Verfasst von Yukie Nakadai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver Cirrhosis, Biliary, Severity of Illness Index, End Stage Liver Disease. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The Model for End-Stage Liver Disease 3.0 (MELD 3.0) was developed in the United States to improve prioritization for liver transplantation (LT); however, its utility in Japanese patients with liver cirrhosis (LC) and acute decompensation (AD) remains invalidated. METHODS: We retrospectively analyzed 312 patients with LC and first-time AD admitted to our institution between 2012 and 2022. Prognostic accuracy of MELD 3.0 was evaluated at 90 and 180 days after admission by comparison with other predictive models. Prognoses according to cirrhosis etiology and contributing factors were also examined. RESULTS: MELD 3.0 demonstrated superior prognostic accuracy at day 180 (C-index: 0.770) compared to the original MELD and MELD Na, although its C-index up to day 90 was comparable to that of MELD and MELD Na. A cut-off value of MELD 3.0 > 20.5 predicted LT or liver-related death at day 180. Patients with primary biliary cholangitis (PBC) had poorer outcomes than non-PBC cases through 180 days and remained an independent risk factor in the Cox proportional hazards model incorporating MELD 3.0. A progressive increase in both MELD 3.0 and total bilirubin from day 0 to day 90 after AD was observed specifically in the PBC group, which may have been associated with the poor prognosis at day 180. CONCLUSIONS: MELD 3.0 was effective in predicting 180-day outcomes in Japanese patients with LC and AD. Progressive bilirubin elevation in PBC may be associated with poor prognosis. These findings suggest that early consideration of LT is warranted in patients with PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. keisuke.ojiro@gmail.com.
- Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
ORCID-Profile: Keisuke Ojiro
Zitieren
APA
Nakadai, Y., Ojiro, K., Kasuga, R., Chu, P. S., Ueno, M., Tabuchi, T., Taniki, N., Usui, S., Hasegawa, Y., Abe, Y., Kitago, M., Obara, H., Kanai, T., & Nakamoto, N. (2026). Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02310-3
Vancouver
Nakadai Y, Ojiro K, Kasuga R, Chu PS, Ueno M, Tabuchi T, et al. Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study. Journal of Gastroenterology. 2026. doi:10.1007/s00535-025-02310-3
BibTeX
@article{Nakadai2026,
author = {Nakadai, Yukie and Ojiro, Keisuke and Kasuga, Ryosuke and Chu, Po-Sung and Ueno, Makoto and Tabuchi, Takaya and Taniki, Nobuhito and Usui, Shingo and Hasegawa, Yasushi and Abe, Yuta and Kitago, Minoru and Obara, Hideaki and Kanai, Takanori and Nakamoto, Nobuhiro},
title = {Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study},
journal = {Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s00535-025-02310-3}
}
EUVIMED